Perspectives on nucleosides, oligonucleotide therapeutics and fine chemical supply chains.
TechnologyOctober 31, 2026
Locked nucleic acid: the “performance lock” that redefined oligonucleotide therapeutics
One methylene bridge, two carbon–oxygen bonds away from the sugar it holds — and an entire class of drugs changes character. How LNA chemistry turned a fragile strand of RNA into a stable, specific, long-acting medicine, and why its supply chain now matters as much as its science.
The third wave of therapeutics runs on chemistry
Nucleic acid drugs have arrived as the third major therapeutic modality, after small molecules and antibodies. Their promise is structural rather than incremental: they can address targets that were long considered undruggable, and they act on dosing intervals measured in weeks or months instead of hours.
Yet none of that efficacy survives contact with a human body on its own. An unmodified oligonucleotide is dismantled by nucleases within minutes and binds its target too weakly to matter. What separates a viable drug from a promising sequence is the chemistry layered onto the backbone and the sugar.
First modalitySmall moleculesThe most common class of medicine. Typically acts on enzymes, ion channels and cell-cycle proteins inside the cell.
Second modalityAntibody drugsBind disease-related cell-surface proteins or signalling pathways, accumulating at the target site to release their payload.
Third modalityNucleic acid drugsDelivered into cells to silence, compensate for or repair a defective gene — treating disease at the message rather than the protein.
Figure 1. Three therapeutic modalities. Nucleic acid drugs act upstream of the protein, which is what lets them reach targets that small molecules and antibodies cannot.
Behind that third wave sits nucleic acid chemistry — and among chemistries, the locked nucleic acid (LNA) family is the benchmark of the third generation. Its structural design and performance have made it a standard tool in both oligonucleotide drug discovery and molecular diagnostics, and it has become the field where innovative manufacturers can break a long-standing international monopoly rather than license around it.
What LNA actually is: a lock on the ribose
Locked Nucleic Acid is a precise chemical edit to the sugar, not the base. A methylene bridge (–CH2–) is installed between the 2′-oxygen and the 4′-carbon of the ribose, forming a stable bicyclic system. The furanose ring, normally free to pucker between several conformations, is pinned permanently into the C3′-endo (North) state.
Figure 2. The LNA scaffold, schematically. A methylene bridge links the 2′-oxygen to the 4′-carbon, converting a flexible five-membered ring into a bicyclic system.
Two pieces of jargon do most of the intimidating work here, and both can be dispatched in a minute.
North (C3′-endo). The conformation natural RNA prefers — imagine standing with the chest open and the head up. The bases sit close together and stack tightly.
South (C2′-endo). The conformation natural DNA usually adopts — a slouched posture, by comparison, with looser base stacking.
Figure 3. The four corners of the sugar-pucker cycle. LNA does not merely prefer the North corner — the bridge removes the ability to leave it, which is why its effects on duplex stability are so much larger than those of flexible 2′-modifications.
LNA’s central advantage is that it imitates RNA’s North conformation and pays for that imitation in advance. Pre-organization is thermodynamically expensive when a strand is free in solution; by building the cost into the monomer, every base pair formed afterwards is cheaper. That single design decision is what separates LNA from earlier generations of modification.
Why modification is not optional: three innate defects
An unmodified oligonucleotide carries three liabilities that no amount of sequence optimization can fix. It is unstable — serum and intracellular nucleases degrade it, so exposure collapses before the drug reaches the tissue. It binds poorly — affinity for the target transcript is weak, which pushes dose and duration in the wrong direction. It is not selective enough — non-specific binding produces off-target effects and toxicity. Together these are the real bottleneck in oligonucleotide development, and chemical modification is the only lever that addresses all three at once.
Poor stabilityDefect 01
Rapid nuclease degradation and short half-life. → LNA: the bicyclic bridge rigidly locks the sugar pucker, reducing nuclease recognition and backbone cleavage, and delivers excellent nuclease resistance.
Weak targetingDefect 02
Low binding affinity for the target RNA. → LNA: the pre-organized C3′-endo geometry optimizes steric arrangement and exposes the bases fully, raising duplex Tm and binding affinity substantially.
Off-target toxicityDefect 03
Non-specific binding and downstream toxicity. → LNA: rigid geometry produces exceptionally strong base stacking and poor tolerance of mismatches, so a single mismatch collapses duplex stability — visible as a large ΔTm.
Figure 4. The three pain points of oligonucleotide drug development, and how LNA chemistry answers each one.
Resistance to nucleases
The bridge does more than stiffen the sugar: it changes how the strand presents itself to enzymes. A rigid, pre-organized backbone is a poorer substrate — recognition is slower, cleavage of the phosphate backbone is suppressed, and the molecule survives long enough to reach the tissue that matters.
Affinity for the target
Because the sugar is already in the duplex-compatible conformation, hybridization does not have to pay the entropic penalty of organizing it. Duplex Tm rises markedly, affinity increases, and the same potency can be reached with a shorter, cheaper, more easily delivered oligonucleotide.
Specificity, and therefore safety
Rigid C3′-endo geometry means very strong base stacking and very little tolerance for error. A single mismatch disrupts the hydrogen bonding and stacking network and duplex stability falls away sharply — the large ΔTm between matched and mismatched duplexes is the physical basis of LNA’s specificity, and the reason off-target-driven toxicity drops at the source rather than being managed downstream.
LNA does not add a new function to an oligonucleotide. It removes the freedom that was working against it.
The market case: a chemistry with a demand curve attached
The clinical success of oligonucleotide drugs has turned modification chemistry into one of the more durable growth segments in biopharma. According to Frost & Sullivan, the global oligonucleotide drug market reached USD 5.7 billion in 2024 and is projected to exceed USD 54.9 billion by 2034 — a CAGR above 20% across the decade. Upstream, the modified nucleoside and phosphoramidite monomer market already exceeded USD 5 billion globally in 2025.
USD 5.7 B
USD 54.9 B
20242034 (estimate)
Figure 5. Global oligonucleotide drug market, 2024 vs. 2034 estimate · CAGR > 20% · Source: Frost & Sullivan.
The pipeline behind that curve is now crowded with LNA-derived chemistry reaching late-stage development and approval:
Ionis — Donidalorsen, built on the third-generation cEt-LNA platform, has been approved by the FDA for hereditary angioedema, reducing attack frequency by 81% with dosing every four weeks.
Alnylam — ALN-2232, an obesity candidate that incorporates LNA modification logic, showed weight-loss effects lasting six months from a single administration, with Phase I scheduled for 2026.
Hygieia Biotech — combining LNA with its proprietary delivery platform, its Lp(a) candidate is designed around a once-a-year injection.
The pattern is consistent: where a programme needs duration, potency and a tolerable safety window at the same time, third-generation sugar chemistry is doing the work.
Making it at scale: inside Innobio Pharm
Chemistry that only works in a flask is not a supply chain. Innobio Pharm has spent two decades on carbohydrate and nucleoside synthesis, building proprietary core technology and industrial-scale engineering experience in ribose and functionalized ribose production. That base supports a fully self-controlled chain — from upstream starting materials through to downstream modified monomers — organized around a “high-fidelity, dual-stable” manufacturing system for oligonucleotide critical raw materials. Classical LNA, cEt and other mainstream third-generation modified nucleosides are now supplied domestically rather than imported.
Modification portfolio
Third generation: LNA, cEt, CN-LNA (hydrophilic cyano-locked nucleic acid)
Second generation: 2′-OMe, 2′-F, 2′-MOE
Backbone: phosphorothioate (PS) and related linkages
Format: nucleosides, phosphoramidite monomers, custom synthesis from milligrams to kilograms
In 2023 the company took on a Beijing municipal major special project for emerging-field science and technology innovation: the scalable manufacturing process for a new hydrophilic cyano-locked nucleic acid, CN-LNA. The technical problem was not conceptual but industrial. CN-LNA demands a long synthetic route, unusually strict reaction control, and suffers from low conversion in constructing the cyano group — a combination that had kept the molecule at laboratory scale.
Innobio Pharm resolved the key steps, completed the project, and moved the process into production. The result is a domestic capability for hydrophilic locked nucleic acid at commercial scale — filling a gap in Chinese supply and ending a foreign monopoly on the high end of the category.
What comes next
A single structural lock redefined what an oligonucleotide could be, and the trajectory of LNA modification makes a broader point: chemistry, not biology alone, has been the engine of this field. The industrialization of CN-LNA pushes the modality further along the axis that matters clinically — longer duration, greater precision, lower toxicity.
As oligonucleotide drugs move out of rare disease and into chronic and common conditions, LNA and its higher-order derivatives will remain the core technical barrier. Delivery platforms, sequence design and backbone chemistry are converging; the programmes that win will be the ones with reliable access to all three.
Innobio Pharm intends to keep working the chemistry — full-chain technology, full-category products, full-process service — as a raw-material and technical partner for oligonucleotide developers worldwide.
Notes. Market figures as cited from Frost & Sullivan in the original source material; clinical data as reported by the respective sponsors. Structural drawings are schematic and intended for communication, not as validated chemical representations.
Working on an LNA or CN-LNA programme? Innobio Pharm supplies LNA, cEt, CN-LNA, 2′-OMe, 2′-F and 2′-MOE phosphoramidites, plus custom synthesis from milligrams to kilograms. Send us your structure and scale requirements for a route assessment, specifications and lead times.
Oligonucleotide Therapeutics in 2026: A Year of Clinical Differentiation
The small nucleic acid sector — siRNA and antisense oligonucleotide (ASO) therapies — has moved decisively beyond proof-of-concept. Across 2026, clinical readouts have shown both remarkable wins and sobering setbacks, and the industry is now competing on clinical value in large indications rather than platform novelty.
Metabolic diseases: the new frontier
Cardiometabolic indications have become the sector's most crowded battleground. Arrowhead's plozasiran, a 25 mg subcutaneous siRNA administered once every three months, delivered median triglyceride reductions of 79–81% at month 12 in two Phase 3 studies of roughly 750 patients with severe hypertriglyceridemia, with a 78% reduction in acute pancreatitis events versus placebo. Meanwhile, GalNAc-siRNA programs targeting INHBE — designed to reduce fat while preserving lean muscle mass — have entered first-in-human trials, positioning oligonucleotides as next-generation weight-management therapies.
Functional cure for hepatitis B within reach?
Combination regimens built around siRNA backbone elebsiran have reported HBsAg loss rates of 22.5% to 42.9% in Phase 2b studies. A chronic hepatitis B ASO developed in partnership between Aligos and a Chinese biopharma was also granted clinical trial approval in China, and GSK's bepirovirsen has entered FDA priority review — clear signals that regulatory milestones for HBV functional cure are accelerating.
Data-driven differentiation
Not every program succeeded. A Phase 3 cardiovascular outcomes study of eplontersen in ATTR cardiomyopathy missed its composite primary endpoint, a reminder that delivery technology alone does not guarantee clinical benefit. In Alzheimer's disease, Biogen's diranersen showed slowed cognitive decline in the 60 mg cohort (up to 50% slowing on MMSE), yet missed its formal dose-response endpoint — the field now awaits Phase 3 confirmation.
What it means for the supply chain
As programs advance toward commercialization, demand is shifting from gram-scale research quantities to kilogram-scale GMP supply of nucleoside building blocks, monomers and intermediates. Purity requirements are tightening accordingly — trace-level impurities that were acceptable for early research now demand rigorous control.
Innobio Pharm supplies nucleosides, phosphoramidites and protected intermediates with rigorous analytical control (HPLC, polarimetry). Contact our team to discuss your project requirements.
Big Pharma Is Doubling Down on siRNA: The Deal-Making Wave Reshaping the Industry
If clinical data defined the science of oligonucleotide drugs in 2026, business development deals defined the economics. The past months have seen some of the largest siRNA licensing agreements on record — and the strategic logic behind them is worth studying.
Deal of the season: AstraZeneca × CSPC
AstraZeneca signed a collaboration, option and license agreement with CSPC Pharmaceutical Group to discover and develop siRNA preclinical candidates against two undisclosed renal targets. The deal structure — a US$30 million upfront payment, up to US$540 million in development milestones, up to US$1.2 billion in sales milestones and tiered royalties — makes it one of the most economically complete small nucleic acid BD transactions of the year. Notably, the collaboration leverages AI-driven molecular design, high-throughput screening and extracellular targeted delivery platforms.
What the deal patterns tell us
AI is now deal infrastructure. Machine-learning sequence design and in silico optimization are being written directly into collaboration agreements as core capabilities.
Chinese innovation is globally licensed. Domestic biotechs are no longer fast-followers — their chemistry modification platforms and delivery technologies are being licensed out to multinational pharma at premium valuations.
Capital is returning. Platform companies continue to raise significant rounds — one Chinese RNA-focused biotech recently closed an oversubscribed RMB 200 million+ financing with top-tier institutional investors across three consecutive rounds.
Established players are deepening ties. Partnerships between siRNA platform companies and big pharma in MASH and metabolic indications are advancing from discovery into candidate nomination and IND-enabling studies.
The upstream implication
Every licensed program multiplies demand for protected nucleosides, phosphoramidite monomers, functionalized controlled-pore-glass (CPG) supports and custom-synthesized intermediates. For CDMOs and raw material suppliers, the window to establish qualified supply relationships is now — during candidate nomination, before GMP lock-in decisions are made.
Beyond the Liver: How Delivery and Chemistry Innovations Are Expanding the Oligonucleotide Map
For two decades, GalNAc conjugation made the liver the default destination for siRNA therapeutics. That era is ending. The industry's most valuable intellectual property is now being created in two areas: reaching tissues beyond the liver, and modifying chemistry to make drugs safer at lower doses.
The extrahepatic delivery race
Central nervous system: ASO programs for Angelman syndrome (obudanersen Phase 3 fully enrolled at 136 patients; rugonersen first patient dosed in the BEACON study) and Alzheimer's disease (diranersen Phase 2) are validating direct CNS delivery via intrathecal administration.
Muscle: FDA has accepted a BLA with priority review for z-rostudirsen, an exon-51-skipping therapy for Duchenne muscular dystrophy, with a PDUFA target date in January 2027.
Adipose tissue: A China-based biotech has received IND clearance for an siRNA that silences ALK7 in fat cells — explicitly designed to reduce fat while preserving lean mass, a differentiated profile for obesity treatment.
Cardiac tissue: Cardiac-targeted RNA candidates have received FDA IND clearance for PRKAG2 syndrome studies, opening the heart as a new therapeutic territory.
Chemistry: "reduce toxicity, increase potency"
Sequence modification platforms are converging on a single mandate — detune toxicity while amplifying potency. Enhanced stabilization chemistry (ESC+ generation conjugates), novel 2'-modifications and optimized phosphorothioate placement are collectively extending tissue half-lives to permit quarterly or even biannual dosing. Every chemical modification, however, begins upstream: with protected nucleosides and phosphoramidite monomers that must themselves be synthesized to exceptional purity.
Why raw materials are the quiet bottleneck
A single late-stage oligonucleotide program can consume tens of kilograms of solid supports and monomers per year. As modification chemistries diversify — each requiring bespoke building blocks — suppliers who can deliver both catalog nucleosides and custom-protected intermediates under consistent quality systems become strategic partners rather than commodity vendors. Analytical transparency matters: full HPLC and polarimetric characterization per batch, documented impurity profiles and scalable synthetic routes from gram to kilogram scale.
Innobio Pharm manufactures nucleosides, phosphoramidite reagents, CPG supports and FMOC derivatives with full analytical documentation. Ask about our customer-centric specifications and packaging options — we are flexible and innovative at finding solutions that work for you.
